1. Dr. James Murphy on Interventional Glaucoma
In this episode of The Glaucoma Mindset, Dr. James Murphy dispels one of the biggest myths in glaucoma care: that cataract surgery and MIGS should be separate decisions. With today’s iTrack™ Advance canaloplasty, surgeons are just millimeters away from restoring physiologic outflow while already inside the eye for cataract extraction. Dr. Murphy explains how combining the two saves time, protects the ocular surface and delivers cleaner outcomes for patients across the glaucoma spectrum.
2. Dr. Larissa Camejo on Interventional Glaucoma
Some may argue that it’s too soon to consider surgery for early glaucoma—but Dr. Larissa Camejo says, “not so fast.”
In this Myths Debunked episode with Nova Eye, she explains how early intervention with MIGS and, more specifically, canaloplasty with iTrack™ Advance, can help delay or even prevent the need for more invasive procedures later on, ultimately preserving vision longer in suitable patients.
Learn more about the iTrack™ Advance and glaucoma care innovations: https://itrack-advance.com/
3. Dr Karl Mercieca on Interventional Glaucoma
In this Interventional Glaucoma Mindset Quick Cut, Dr. Karl Mercieca takes aim at some of the most persistent myths around IG and canaloplasty. Rather than making glaucoma specialists irrelevant, he argues that when his comprehensive ophthalmologist, cataract and/or anterior segment surgeon peers adopt interventional glaucoma appropriately, it frees glaucoma specialists to focus on the complex glaucoma patients who truly need their time and expertise.
He also pushes back on the idea that drop non-adherence is “overblown,” pointing to what every clinic sees daily: red, uncomfortable eyes, forgetfulness and studies showing that many patients stop taking their medication within months. Against that backdrop, he highlights why he views iTrack™ Advance as a versatile tool rather than a single-purpose device, with the ability to tailor canaloplasty and, where indications allow, combine with trabeculotomy. For him, the anatomical and physiological changes seen after canaloplasty support a lasting therapeutic effect, not just a temporary “flush.”
Visit https://itrack-advance.com/ for more information.
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
4. Dr Karsten Klabe on Interventional Glaucoma
For Dr. Karsten Klabe, the idea that glaucoma drops are the “safe, benign” starting point does not match what he sees in clinic. Prescribing is simple; living with the drops is not. Over years, ocular surface disease, low-grade inflammation and systemic side effects slowly stack up, especially for older patients who already find bottles, bottles and more bottles hard to manage.
That reality is what pushed him to bring canaloplasty forward in his treatment thinking. With the iTrack™ Advance, canaloplastu lets him work with Schlemm’s canal rather than against it, using viscodilation to open the full 360° outflow pathway while preserving tissue. As device designed tomatch the delicacy of the canal, iTrack™ Advancei fits comfortably into an earlier, more interventional mindset.
Explore how this could fit into your own glaucoma strategy at https://itrack-advance.com/.
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
